Načítá se...
Age Disparity in the Dissemination of Imatinib for Treating Chronic Myeloid Leukemia
BACKGROUND: Imatinib is a highly effective treatment for chronic myeloid leukemia (CML) that was approved by the Food and Drug Administration in 2001, and thereafter rapidly became front line therapy. This study characterized the prevailing chronic myeloid leukemia therapies in the United States and...
Uloženo v:
| Hlavní autoři: | , , , , , , |
|---|---|
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
2010
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2913144/ https://ncbi.nlm.nih.gov/pubmed/20670732 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.amjmed.2010.03.018 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|